Dublin-based Medtronic plc will start a trial to assess two drug-eluting stents (DES) with a shorter-than-standard, one-month regimen of dual antiplatelet therapy (DAPT) in patients who are at high bleeding risk. Current drug-eluting stent guidelines call for six months of the accompanying drug therapy, which can be risky for older patients and others at risk for excessive bleeding. Read More
